Physician profile
Todd Ramer
NPI 1013142462
$4,271.03
in general payments reported to CMS, 2019-2025
31 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what 89% of Acute Care (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $137).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,135 · 2022: $1,234 · 2023: $324 · 2024: $469 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,826 · Education: $76.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,826.06 |
| Education | $76.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $782.54 | 2022 | |
| Boston Scientific Corporation | $664.00 | 2021-2024 | Wavewriter Alpha Prime 16 |
| Abbvie INC. | $498.89 | 2021-2025 | |
| Ucb, INC. | $404.23 | 2023-2025 | Fintepla, Briviact, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $363.30 | 2022-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Allergan, INC. | $338.35 | 2021-2022 | |
| Eisai INC. | $167.27 | 2022-2025 | |
| Sk Life Science, INC. | $167.13 | 2023-2025 | |
| Pfizer INC. | $114.58 | 2024-2025 | |
| Livanova USA, INC. | $107.00 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Celgene Corporation | $85.85 | 2021 | |
| Janssen Pharmaceuticals, INC | $62.05 | 2021 | |
| Alexion Pharmaceuticals, INC. | $54.58 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $51.74 | 2025 | |
| Abbott Laboratories | $48.59 | 2025 | Infinity |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $36.63 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $33.74 | 2021 | |
| Jazz Pharmaceuticals INC. | $30.78 | 2025 | |
| Kyowa Kirin, INC. | $29.23 | 2022 | |
| Lilly USA, LLC | $25.58 | 2025 | Kisunla |
| Azurity Pharmaceuticals, INC. | $23.97 | 2024 | |
| Acadia Pharmaceuticals INC | $22.76 | 2025 | Nuplazid |
| Lundbeck LLC | $22.33 | 2024 | Vyepti |
| Harmony Biosciences LLC | $22.17 | 2023 | Wakix |
| Supernus Pharmaceuticals, INC. | $21.72 | 2025 | Qelbree |
| Avanir Pharmaceuticals, INC. | $18.74 | 2021 | |
| Neurelis, INC. | $16.85 | 2023 | Valtoco |
| Ipsen Biopharmaceuticals, INC | $15.78 | 2022 | |
| Biogen, INC. | $14.76 | 2022 | |
| Ani Pharmaceuticals, INC. | $13.98 | 2022 | |
| Mdd US Operations, LLC | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Ramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.